Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
about
Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration.Cerebrospinal fluid proteome profile in multiple sclerosis.The Genetic Challenges and Opportunities in Advanced Heart FailureTafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trialIn vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy.Molecular diagnosis of inheritable neuromuscular disorders. Part II: Application of genetic testing in neuromuscular disease.A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).Amyloid neuropathies.Endoscopic Findings of Small-Bowel Lesions in Familial Amyloid Polyneuropathy: A Case Report.Ophthalmic manifestations in a Chinese family with familial amyloid polyneuropathy due to a TTR Gly83Arg mutation.Transthyretin-related hereditary amyloidosis with recurrent vomiting and renal insufficiency as the initial presentation: A case reportSystemic amyloidoses.Progress in the treatment of small fiber peripheral neuropathy.Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation.Vitrectomy for vitreous amyloidosis.Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy.Phenotypic expression of familial amyloid polyneuropathy in Brazil.Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.Genetics of familial amyloidotic polyneuropathy in a Hong Kong Chinese kindred.A novel transthyretin mutation V32A in a Chinese man with late-onset amyloid polyneuropathy.Coexistence of familial transthyretin amyloidosis ATTR Val30Met and spinocerebellar ataxia type 1 in a Japanese family--a follow-up autopsy report.Gastrointestinal Amyloidosis: Approach to Treatment.Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies.An aggressive form of familial amyloid polyneuropathy caused by a Glu54Gly mutation in the transthyretin gene.Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese.Evidence that glial cells attenuate G47R transthyretin accumulation in the central nervous system.Extended phenotype in the transthyretin Tyr77 familial amyloid polyneuropathy.Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.Destabilization of transthyretin by pathogenic mutations in the DE loop.Bullous formation in a patient with familial amyloid polyneuropathy type I.Understanding the Disease Course and Therapeutic Benefit of Tafamidis Across Real-World Studies of Hereditary Transthyretin Amyloidosis with Polyneuropathy: A Proof of Concept for Integrative Data Analytic Approaches.Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.
P2860
Q33294428-2FADC99C-F8E4-4FB6-B02F-415C080F19C5Q33299647-6D2F0BCA-27D6-41A0-AC10-E6EFD27769A2Q33653498-6C45CF70-F8D6-41D6-BF6F-22B935D306FFQ33903527-3D0CA572-7A00-468C-B60F-F5D587DA5E52Q35119383-1A9A11AF-1924-4070-9C40-E433E6B8DDE3Q35280661-265D4FC5-73C1-4CE1-9786-9DD710A13F28Q35830457-78590766-25E0-4E97-A251-6A4D9B0CCAA9Q36036959-13DBED7D-14A9-4256-8AC3-104B15884532Q36142867-3D362A51-48A3-473E-BD31-F0BF7A5FCF23Q36338381-ADF00D8F-4CD2-4A6A-A952-5C76D39A1454Q36493200-DF584753-594E-4777-A947-086EDEE61B48Q36822622-2CCF2EE9-E5EE-4345-82BF-CA81F03C5DE1Q37474592-31AE3E1F-6B9A-4C6D-9D6E-0BA78F855CC1Q37696818-9C036B66-013E-46D6-838B-ACCC1E6DBA8EQ38085664-677C36DF-2C4B-4B90-B74C-67B052A29B4FQ38349089-DC4419F7-A339-48B5-8D14-B75053CC5D9AQ41856630-5E6087E6-90C9-452B-A2AA-EF17E33A4D59Q42142323-F93A5D73-9956-4D27-8402-C31BF3C21FDAQ42646054-606009B0-C2A4-4C63-AC6E-1E27973E746BQ42652254-9AD6829E-CD8C-487F-98B2-00937CA62D62Q43820626-3648CA1D-E667-406D-95BA-365892F91CC4Q44447914-3060EA90-1889-415B-8BFA-C6C2FDAACB0BQ44809234-4FBC8A5D-8B7A-42D7-934E-7E4C8643B510Q45137785-3F777A4A-EEAC-4CD1-B90C-F32844291442Q46144079-E46FC6A2-EE63-4CD6-83F9-39AA38B19BB0Q46239296-8C9BF525-5E8B-41C1-8888-37EBD64C7E6EQ46625962-5D1A8140-9487-4F54-955A-7C229E86FE7DQ46925129-79795170-3CB8-4DEB-B3C5-ACCE9F5CF108Q47727255-48D2511F-23ED-4783-9371-CBBCE084CD9EQ50474320-E14F5325-559A-43CA-9D4D-3149B8308393Q50485049-C2E5A227-E408-480C-BEB2-9B3CDFFA7A10Q54451017-04CB4952-BE0E-413C-AC59-9F25BCB31D78Q54689090-E68105EF-E282-41FB-9AE8-E7E0BF26CD1AQ55215108-EF1B4D65-2912-4F1E-A04F-3A24F2248CF6Q55280701-B20FB56A-E58B-4BB5-9D40-3A651D9FD707
P2860
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@ast
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@en
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@nl
type
label
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@ast
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@en
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@nl
prefLabel
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@ast
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@en
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@nl
P2093
P356
P1433
P1476
Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.
@en
P2093
P304
P356
10.1212/WNL.56.4.431
P407
P577
2001-02-01T00:00:00Z